Dr Reddy's Laboratories jumped 4.76% to Rs 3,890.10 at 15:25 IST on BSE after consolidated net profit rose 13.67% to Rs 625.65 crore on 6.62% rise in total income to Rs 3770.25 crore in Q1 June 2015 over Q1 June 2014.
The company announced results during market hours today, 30 July 2015.
Meanwhile, the S&P BSE Sensex was up 135.20 points or 0.49% at 27,698.63.
On BSE, so far 99,257 shares were traded in the counter as against average daily volume of 16,138 shares in the past one quarter.
The stock hit a high of Rs 3,915 and a low of Rs 3,721.05 so far during the day. The stock had hit a record high of Rs 3,960 on 23 July 2015. The stock had hit a 52-week low of Rs 2,711.90 on 11 August 2014.
The stock had outperformed the market over the past one month till 29 July 2015, rising 5.46% compared with Sensex's 0.3% decline. The scrip had also outperformed the market in past one quarter, gaining 9.96% as against Sensex's 1.24% gain.
The large-cap pharma company has equity capital of Rs 85.28 crore. Face value per share is Rs 5.
Dr Reddy's Laboratories' earnings before interest, taxation, depreciation and amortization (EBITDA) rose 12% to Rs 990 crore in Q1 June 2015 over Q1 June 2014. EBITDA margin increased to 26.5% in Q1 June 2015 compared with 25.2% in Q1 June 2014. Gross profit margin increased by 1.8% to 61.1% in Q1 June 2015 compared with Q1 June 2014.
Commenting on the results, Dr Reddy's co-chairman and CEO, GV Prasad said, first quarter results reflect healthy performance. The company has been able to achieve these results despite limited new launches and headwinds in the form of currency devaluation in key emerging markets. As company continues to further strengthen product portfolio and drive new launches, the company is well positioned for the next phase of growth, he added.
Powered by Capital Market - Live News
